Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
The portfolio includes foundational patents on the production, composition, and commercial use of NR
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
This marks the first partnership between Pfizer and Cipla in India
The company operates a chain of mid-sized multi-speciality hospitals
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Subscribe To Our Newsletter & Stay Updated
